Applied Clinical Trials
Protocol complexity, as measured by the number of unique procedures and their frequency and the number of subject eligibility criteria, has risen dramatically in comparisons of protocol characteristics between two time periods, 2000-2003 and 2004-2007.
Protocol complexity, as measured by the number of unique procedures and their frequency and the number of subject eligibility criteria, has risen dramatically in comparisons of protocol characteristics between two time periods, 2000-2003 and 2004-2007. The burden on investigative sites to administer these procedures has also risen sharply. Tufts CSDD research has shown that higher levels of protocol complexity and execution burden are associated with study conduct delays, longer cycle times, more protocol amendments, and poorer patient recruitment and retention rates. Phase I and Phase IV protocols have seen the largest increases in complexity and work burden as drug developers have sought to gather more clinical research data in earlier phase clinical trials and as post-approval clinical research studies have become more robust. Phase III protocols grew the least in terms of complexity and execution burden during the observation period perhaps reflecting sponsors' efforts over the last decade to control rising costs and demands of large, later-stage clinical research programs.
—Tufts Center for the Study of Drug Development, http://csdd.tufts.edu.
Rising Protocol Complexity and Execution Burden
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.